Maccura Biotechnology Co.Ltd Stock
Equities
300463
CNE1000020H3
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.48 CNY | -1.54% |
|
-1.88% | -23.82% |
| Sep. 05 | Maccura Biotechnology Unit Gets China Nod for Virus Detection, Blood Type Devices | MT |
| Aug. 14 | Maccura Biotechnology Gets Nod to Market Two Medical Devices | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Enjoy this offer
* See conditions on site
| Capitalization | 6.97B 982M | P/E ratio 2024 * |
16.2x | P/E ratio 2025 * | 12.9x |
|---|---|---|---|---|---|
| Enterprise value | 9.23B 1.3B | EV / Sales 2024 * |
2.28x | EV / Sales 2025 * | 2.06x |
| Free-Float |
59.73% | Yield 2024 * |
3.05% | Yield 2025 * | 4.44% |
More valuation ratios
* Estimated data
More news
| 1 day | -1.54% | ||
| 1 week | -1.88% | ||
| Current month | -5.36% | ||
| 1 month | -3.04% | ||
| 3 months | -5.67% | ||
| 6 months | -13.62% | ||
| Current year | -23.82% |
1 week
11.43
11.98
1 month
11.2612.99
Current year
9.9015.23
1 year
9.9017.38
3 years
9.9038.24
5 years
9.9065.24
10 years
9.9065.24
| Director | Title | Age | Since |
|---|---|---|---|
Ming Jian Wu
CEO | Chief Executive Officer | 49 | 01-12-31 |
Shan Yin
DFI | Director of Finance/CFO | 44 | 21-10-25 |
Wen Jun Zhang
IRC | Investor Relations Contact | - | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Dai Guo Fu
BRD | Director/Board Member | 60 | 19-01-21 |
Yong Tang
CHM | Chairman | 61 | 94-10-19 |
Qi Lin Liu
BRD | Director/Board Member | 58 | 93-12-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.54% | -1.88% | -20.66% | -59.06% | 982M | ||
| -0.09% | +4.26% | +18.85% | -2.31% | 14.41B | ||
| +0.62% | +3.23% | +10.74% | +52.60% | 7.69B | ||
| +1.46% | +3.50% | +59.06% | +329.41% | 7.33B | ||
| +1.91% | +2.82% | +12.43% | -48.46% | 6.15B | ||
| -1.27% | -2.06% | +81.27% | -53.68% | 3.29B | ||
| -0.83% | -4.10% | -15.91% | -23.22% | 3.12B | ||
| -0.80% | +3.85% | -54.80% | -85.63% | 2.7B | ||
| -1.87% | -5.37% | +9.95% | +466.43% | 2.62B | ||
| +4.55% | +2.30% | +66.81% | -13.32% | 2.51B | ||
| Average | +0.21% | +0.75% | +16.77% | +56.28% | 5.08B | |
| Weighted average by Cap. | +0.43% | +2.20% | +21.79% | +61.81% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 3.06B 431M | 3.38B 476M |
| Net income | 434M 61.16M | 544M 76.76M |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
1,675
Calendar
2024-10-22
- Q3 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-13 | 11.48 ¥ | -1.54% | 3,819,600 |
| 24-09-12 | 11.66 ¥ | -0.68% | 3,260,000 |
| 24-09-11 | 11.74 ¥ | -0.09% | 2,767,100 |
| 24-09-10 | 11.75 ¥ | -0.09% | 3,412,348 |
| 24-09-09 | 11.76 ¥ | +0.51% | 4,291,099 |
End-of-day quote Shenzhen S.E., September 12, 2024
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
11.48CNY
Average target price
13.79CNY
Spread / Average Target
+20.12%
Annual profits - Rate of surprise
- Stock Market
- Equities
- 300463 Stock